Prospective randomised clinical trial of intravitreal bevacizumab versus triamcinolone in eyes with diabetic macular oedema undergoing cataract surgery: 6-month results

British Journal of Ophthalmology

Volumn 103, Issue 12, 2019, Pages 1753-1758

  Kandasamy, Rathika ^a   Constantinou, Marios ^a   Rogers, Sophie L ^a   Sandhu, Sukhpal Singh ^a   Wickremasinghe, Sanjeewa ^a   Al Qureshi, Salmaan ^a   Lim, Lyndell L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

bevacizumab; cataract surgery; diabetic macular oedema; randomised clinical trial; triamcinolone

Indexed keywords

BEVACIZUMAB; TRIAMCINOLONE; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ALGORITHM; ARTICLE; BEST CORRECTED VISUAL ACUITY; CATARACT EXTRACTION; CENTRAL MACULAR THICKNESS; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; OUTCOME ASSESSMENT; PARALLEL DESIGN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VISION; BIOMETRY; COMPARATIVE STUDY; DIABETIC RETINOPATHY; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RETINA; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BIOMETRY; CATARACT EXTRACTION; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 85062322329     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2018-313437     Document Type: Article

References (35)

1. Mitchell P, Annemans L, Gallagher M, et al. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the restore trial. Br J Ophthalmol 2012;96:688-93.
2. Dowler Jet al. The natural history of macular edema after cataract surgery in diabetes. Ophthalmology 1999;106:663-8.
3. Krepler K, Biowski R, Schrey S, et al. Cataract surgery in patients with diabetic retinopathy: visual outcome, progression of diabetic retinopathy, and incidence of diabetic macular oedema. Graefe's Arch Clin Exp Ophthalmol 2002;240:735-8.
4. Zaczek A, Olivestedt G, Zetterström C. Visual outcome after phacoemulsification and IOL implantation in diabetic patients. Br J Ophthalmol 1999;83:1036-41.
5. Bressler SB, Baker CW, Almukhtar T, et al. Pilot study of individuals with diabetic macular edema undergoing cataract surgery. JAMA Ophthalmol 2014;132:224-6.
6. Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis. Br J Ophthalmol 2006;90:697-701.
7. Funatsu H, Noma H, Mimura T, et al. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009;116:73-9.
8. Imai S, Otsuka T, Naito A, et al. Triamcinolone acetonide suppresses inflammation and facilitates vascular barrier function in human retinal microvascular endothelial cells. Curr Neurovasc Res 2017;14.
9. Kriechbaum K, Prager S, Mylonas G, et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon a) for treatment of diabetic macular edema: one-year results. Eye 2014;28:9-16.
10. Aksoy S, Yilmaz G, Akkoyun I, et al. Comparison of intravitreal bevacizumab and triamcinolone acetonide theraphies for diffuse diabetic macular edema. Int J Ophthalmol 2015;8:550-5.
11. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-61.
12. Isaac DLC, Abud MB, Frantz KA, et al. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study. Acta Ophthalmol 2012;90:56-60.
13. Lim LL, Morrison JL, Constantinou M, et al. Diabetic Macular Edema at the time of Cataract Surgery trial: a prospective, randomized clinical trial of intravitreous bevacizumab versus triamcinolone in patients with diabetic macular oedema at the time of cataract surgery-preliminary 6 month results. Clin Exp Ophthalmol 2016;44:233-42.
14. JWR T. Applied longitudinal data analysis for epidemiology: a practical guide. 2nd edn. Cambridge: Cambridge University Press, 2013.
15. Habib MS, Cannon PS, Steel DHW. The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabeticfoveal oedema and cataract. BMC Ophthalmol 2005;5.
16. Lam DSC, Chan CKM, Mohamed S, et al. Phacoemulsification with intravitreal triamcinolone in patients with cataract and coexisting diabetic macular oedema: a 6-month prospective pilot study. Eye 2005;19:885-90.
17. Takata C, Messias A, Folgosa MS, et al. Intravitreal injection versus subtenon infusion of triamcinolone acetonide during cataract surgery in patients with refractory diabetic macular edema. Retina 2010;30:562-9.
18. Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen JL, et al. Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab. Retina 2009;29:530-5.
19. Takamura Y, Kubo E, Akagi Y. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery. Ophthalmology 2009;116:1151-7.
20. Chen CH, Liu YC, Wu PC. The combination of intravitreal bevacizumab and phacoemulsification surgery in patients with cataract and coexisting diabetic macular edema. J Ocul Pharmacol Ther 2009;25:83-90.
21. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011;152:686-94.
22. Roh MI, Kim HS, Song JH, et al. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 2009;116:80-6.
23. Dong N, Xu B, Chu L, et al. Study of 27 aqueous humor cytokines in type 2 diabetic patients with or without macular edema. PLoS One 2015;10:e0125329.
24. Jonas JB, Jonas RA, Neumaier M, et al. Cytokine concentration in aqueous humor of eyes with diabetic macular edema. Retina 2012;32:2150-7.
25. Maturi RK, Glassman AR, Liu D, et al. Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: a DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol 2018;136:29-38.
26. Joe AW, Wickremasinghe SS, Gillies MC, et al. Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long-term treatment with bevacizumab. Clin Exp Ophthalmol 2018. [Epub ahead of print: 06 Aug 2018].
27. Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol 2006;142:405-12.
28. Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007;114:525-36.
29. Murakami T, Yoshimura N. Structural changes in individual retinal layers in diabetic macular edema. J Diabetes Res 2013;2013:1-11.
30. Alasil T, Keane PA, Updike JF, et al. Relationship between optical coherence tomography retinal parameters and visual acuity in diabetic macular edema. Ophthalmology 2010;117:2379-86.
31. Wong RLM, Lee JWY, Yau GSK, et al. Relationship between outer retinal layers thickness and visual acuity in diabetic macular edema. Biomed Res Int 2015;2015:1-5.
32. Eliwa TF, Hussein MA, Zaki MA, et al. Outer retinal layer thickness as good visual predictor in patients with diabetic macular edema. Retina 2017.
33. Ahmadabadi HF, Mohammadi M, Beheshtnejad H, et al. Effect of intravitreal triamcinolone acetonide injection on central macular thickness in diabetic patients having phacoemulsification. J Cataract Refract Surg 2010;36:917-22.
34. VanderBeek BL, Bonaffini SG, Ma L. The association between intravitreal steroids and Post-Injection endophthalmitis rates. Ophthalmology 2015;122:2311-5.
35. Eadie BD, Etminan M, Carleton BC, et al. Association of repeated Intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA ophthalmol 2017;135:363-8.